Exploring federal cannabis rescheduling delays, tightened Texas hemp limits, and Massachusetts' adult-use repeal initiative.

Georgia, Vermont and California officials say DEA has offered little implementation guidance after marijuana moved to Schedule III for state medical programs, leaving labeling, taxes and inspections unclear.

A new DEA registration pathway pulls state-licensed medical cannabis manufacturers, distributors, and labs into the federal Schedule III framework—potentially easing 280E tax pain.

DEA adds dedicated federal registration paths for state-licensed medical marijuana manufacturers, distributors, and testing labs, expanding beyond dispensaries amid ongoing Schedule III transition.

DEA’s 2026 Drugs of Abuse update says no deaths from marijuana overdose and reflects federal moves toward Schedule III for certain cannabis products. Here’s what it means in practice.

Treasury and the IRS say tax guidance tied to cannabis rescheduling is a top priority for 2026–2027, with big implications for Section 280E and mixed medical/adult-use operators.

A December 18, 2025 executive order shifts cannabis from Schedule I to Schedule III. Here’s how that could reshape taxes, research, and patient access across the DMV.

A White House move to shift marijuana from Schedule I to Schedule III could ease taxes and research hurdles—but it won’t legalize sales or delivery overnight.

Rescheduling momentum is real, but tax experts say cannabis businesses may remain under 280E for the entire 2025 tax year. Here’s what that means for DMV operators and delivery services.

A website tweak sparked headlines, but TSA says nothing changed. Here’s what airport screening still means for medical patients and DMV travelers.

A DEA administrative law judge issued a stay on the wider adult-use rescheduling review, weighing a GAO report’s admission and extra briefing. The pause does not alter April’s medical marijuana move to Schedule III, per mg Magazine.

A DEA administrative judge paused the cannabis rescheduling hearing to consider a GAO watchdog report on process gaps. A DEA response is due by October 13, adding delay and uncertainty.

State regulators say DEA guidance is essential to align medical cannabis rules with the new Schedule III status—especially for delivery, labeling, and patient access across the DMV.

A new GAO report says DEA and FDA lack clear drug-scheduling procedures just as an ALJ reviews moving cannabis to Schedule III and court fights continue.

A little-known 1969 cannabis journal argued the core points the DEA just made on rescheduling—raising new stakes for patients, researchers, and the DMV in 2026.

A new appellate decision threatens the enforceability of cannabis deals in federal court—and it reshapes leverage, drafting strategy, and risk for delivery, retail, and investors.

A D.C. Circuit panel declined to pause AG Todd Blanche’s move placing certain marijuana activity in Schedule III, leaving the framework in effect while challenges proceed.

Schedule III didn’t unlock banking. One credit union’s model shows how cannabis businesses get compliant access to payments—plus what DMV operators should watch next.

A federal appeals court left the Attorney General’s limited Schedule III move in place as Congress bickers over hemp. Here’s what DMV delivery operators and consumers should watch now.

Two federal marijuana sentences were cut as Washington debates moving some cannabis to Schedule III. Here’s what’s known now—and what DMV residents should watch.